Prescient reports blockbuster results in breast cancer
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX) has today announced its most significant clinical milestone to date — the highly encouraging results of its PTX-200 Phase 1b Breast Cancer trial.
Patients evaluable for efficacy in the PTX-200 Phase 1b breast cancer trial showed an overall response rate of 50%, against the predicted industry average response rate of 25% with only chemotherapy drug paclitaxel.
In the five patients with locally advanced disease, two (or 40%) had pathologic complete responses — meaning total eradication of cancer — and three patients had an Overall Response Rate (ORR) of 100%.
The Phase 1b trial evaluated PTX-200 in combination with paclitaxel in women with HER2-negative breast cancer, including ER-/PR- (triple negative) and ER+ breast cancer. The results were particularly favourable for women with ER+ breast cancer — with a ‘pathological complete response’ (pCR) of 50% and ORR of 75% in this category, as shown below:
Of patients with locally advanced disease, which is PTX’s focus for the Phase 2 study, there was a total of two pCRs (40%) and three PRs (60%) for an ORR of 100%, as shown below:
Of course, it should be noted that PTX is still a speculative stock and anything can happen. Investors should seek professional financial advice if considering this stock for their portfolio.
More detail on PTX-200 trials
The Phase 1b trial was undertaken with the leadership of renowned breast cancer specialist Professor Joseph Sparano, MD, and the H. Lee Moffitt Cancer Center in Tampa (Moffitt) at the Montefiore Medical Center, Albert Einstein College of Medicine in New York.
The Phase 1b dosed 28 patients in total, resulting in 10 patients who were evaluable for clinical response — of these, five had locally advanced disease and five had metastatic disease.
PTX is currently in a Phase 2 trial for women with HER2 negative locally advanced breast cancer, with five of the patients of the Phase 1b study qualifying for assessment of Phase 2 data.
The company’s Phase 2 trial will be in 26 patients using a “two-stage Simons MinMax Design”. This means that, provided at least three pCRs are observed in the first 11 patients of the Phase 2 trial, it will expand to include a further 15 patients. At this stage, PTX already have two pCRs within the first five patients, leaving it in a good position to eventually expand the Phase 2 trial.
For the purposes of the PTX-200 trials, assessment of disease falls into several different categories according to a patient’s response to therapy:
• Pathological Complete Response (or Complete Response) (pCR or CR): meaning complete eradication of cancer from the patient;
• Partial Response (PR): partial but not complete eradication of cancer;
• Stable Disease (SD): cancer has not progressed, but neither has it diminished; and
• Progressive Disease (PD): cancer has progressed.
To put PTX’s results into perspective, for women with locally advanced ER+ HER2 negative breast cancer, typical expectations are pCR rates of 16% (11-22%) and ORR of 25%.
In PTX’s Phase 1b trial, the ORR was 50%, and in the five patients with locally advanced diseases, 40% had pCRs, and three had an ORR of 100%.
PTX is at the forefront of cutting edge research that aims to better target drug therapies to improve outcomes for the patient — in terms of effectiveness in killing cancer cells, as well as reducing treatments’ toxic side-effects.
It is currently in human clinical trials with two innovative drugs which ‘turn off the switch’ that would otherwise allow cancerous cells to grow via the important Akt and Ras pathways.